Exparel^® (Bupivacaine Liposome Injectable Suspension) as Adjunctive Pain Control in Adult Tonsillectomy: Reducing...

Area of Science:

• Anesthesiology
• Pain Management
• Surgical Recovery

Background:

• Tonsillectomy is associated with significant post-operative pain, often requiring opioid analgesics.
• Managing post-operative pain effectively is crucial for patient recovery and satisfaction after tonsillectomy.

Purpose of the Study:

• To evaluate the efficacy of Exparel (bupivacaine liposome suspension) as an adjunct to standard care for pain management in adult tonsillectomy patients.
• To compare post-operative pain scores and opioid consumption between patients receiving Exparel plus standard care and those receiving standard care alone.

Main Methods:

• A randomized controlled trial was conducted in a community hospital setting.
• Adult tonsillectomy patients were randomized to receive either Exparel plus standard care or standard care alone.
• Pain levels and opioid use were monitored via daily pain diaries and electronic medical records.

Main Results:

• The Exparel + standard care group reported significantly lower pain scores on post-operative day 3 compared to the control group.
• Mean pain scores decreased in the Exparel group while increasing in the control group.
• Opioid use, specifically oxycodone, was significantly reduced in the Exparel group between post-operative days 3 and 5.

Conclusions:

• Exparel bupivacaine liposome suspension, when used as an adjunct to standard care, can decrease post-operative pain and opioid requirements in adult tonsillectomy patients.
• These findings suggest Exparel may be a valuable tool for optimizing pain management protocols in adult tonsillectomy.
• This study provides evidence to guide best practices for post-tonsillectomy pain control.